News

HAYA Therapeutics raises CHF 18 million Seed financing to advance anti-fibrotic therapies targeting long non-coding RNAs

May 20, 2021

HAYA Therapeutics raises CHF 18 million Seed financing to advance anti-fibrotic therapies targeting long non-coding RNAs

May 20, 2021

Share:

Other news

HAYA Therapeutics wins the top prize at the TOP 100 Swiss Startup Award 2023

Junk DNA: how the dark genome is changing RNA therapies

The mystery of the human genome's dark matter

RNA companies to watch over the next 12 months

Drug discovery startups set to take-off

Clarivate Identifies Seven Innovators in New RNA Technology Companies to Watch Report

18 European techbio startups to watch — according to investors

HAYA Therapeutics: sur la piste de la fibrose

What dark matter means for the future of therapeutics

7 Top BioPharma Startups & Companies (Vaud)

Delivery & Safety Top Concerns as BIO-Europe Plumbs Future of Gene Therapy

HAYA, RenBio Launch with Sights Set on Clinic

Biotech Haya Therapeutics shouts 'hiya!' as it emerges from stealth with seed funding

A new RNA startup looks to reimagine heart treatments, with eyes set on Entresto